Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Increased to $25.00 by Analysts at Barclays

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by Barclays from $22.00 to $25.00 in a research note published on Wednesday, Benzinga reports. Barclays currently has an overweight rating on the stock.

TEVA has been the topic of a number of other research reports. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday. Jefferies Financial Group upped their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Wednesday, July 10th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Trading Up 0.1 %

Shares of Teva Pharmaceutical Industries stock opened at $18.41 on Wednesday. Teva Pharmaceutical Industries has a 12-month low of $8.07 and a 12-month high of $19.08. The firm’s 50 day simple moving average is $18.02 and its two-hundred day simple moving average is $16.72. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, analysts expect that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Maple Rock Capital Partners Inc. raised its position in shares of Teva Pharmaceutical Industries by 68.3% during the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after purchasing an additional 1,770,000 shares during the last quarter. Iron Triangle Partners LP raised its holdings in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $23,115,000. Davidson Kempner Capital Management LP lifted its position in shares of Teva Pharmaceutical Industries by 152.5% in the second quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock valued at $28,689,000 after acquiring an additional 1,066,150 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after purchasing an additional 1,031,400 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.